CN105902532A - Anti-bacterial medicine, preparation method and application thereof - Google Patents
Anti-bacterial medicine, preparation method and application thereof Download PDFInfo
- Publication number
- CN105902532A CN105902532A CN201610249267.3A CN201610249267A CN105902532A CN 105902532 A CN105902532 A CN 105902532A CN 201610249267 A CN201610249267 A CN 201610249267A CN 105902532 A CN105902532 A CN 105902532A
- Authority
- CN
- China
- Prior art keywords
- compound
- bacterial
- medicine composition
- preparation
- bacterial drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medicines and particularly relates to an anti-bacterial medicine composition. The medicine composition includes a compound I and a compound II as active components, wherein the mass percentages of the compound I and the compound II are respectively 70% and 30%. The compound I is Cyclomarinone while the compound II is Maristachones E. The medicine composition has strong effects of inhibiting escherichia coli, pseudomonas fluorescens, staphylococcus aureus, proteusbacillus vulgaris and cryptococcus neoformans. The medicine composition is disclosed as an anti-bacterial compound for the first time, has strong inhibition activity on bacteria, has outstanding substantive features, and has significant improvement on prevention and treatment of bacterial infection.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of anti-bacterial drug and its preparation method and application.
Background technology
Antibacterials are widely used in acquired immune deficiency syndrome (AIDS), organ transplantation and Chronic consumptions (such as cancer, sugar as routine administration
Urine disease, uremia etc.) treatment, although the antimicrobial agent used clinically at present is to the curative effect of skin and superficial place infection relatively
Good, but the cumulative toxicity of these antibacterials is relatively strong, usually causes the stimulation of lesions of liver and kidney, digestive tract, dizziness, allergy etc., institute
To find one of unique novel antibacterial medicine focus becoming current medicament research and development of the mechanism of action.
The compound Cyclomarinone that the present invention relates to and Maristachones E is one and delivers (Almeida in 2013
C, et al., Unprecedented polyketides from a marine sponge-associated Stachylidium
Sp.J Nat Prod, 2013,76 (3): 322-326.) noval chemical compound, this compound has brand-new framework types, this
Compound Cyclomarinone and Maristachones E compositions purposes in preparing anti-bacterial drug that invention relates to belong to
In first public.
Summary of the invention
Do not find that it has in it is an object of the invention to study according to existing Cyclomarinone and Maristachones E anti-
The present situation of the report of bacterial activity, it is provided that Cyclomarinone and Maristachones E compositions is at preparation antibacterium medicine
Application in thing.
A kind of anti-bacterial drug compositions, the active component of said composition is made up of compound I and compound II, said composition
The mass percent of middle compound I and compound II is respectively 70% and 30%, and described compound I is Cyclomarinone,
Shown in structure such as formula (I), described compound II is Maristachones E, shown in structure such as formula (II):
Described anti-bacterial drug compositions, preparation method is according to quality hundred by the powder of compound I and the powder of compound II
Mark respectively 70% and 30% is sufficiently mixed, and adds adjuvant, makes preparation.
Described anti-bacterial drug compositions, adjuvant is dextrin or starch.
The application in preparing anti-bacterial drug of the described anti-bacterial drug compositions.
Described anti-bacterial drug, antibacterial is escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, new
Raw cryptococcus.
Experimentation show the compositions of compound Cyclomarinone and Maristachones E have suppression escherichia coli,
Fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, the effect of neogenesis cryptococcus, thus Cyclomarinone and
The compositions of Maristachones E can as having the compound of antibacterial action, and be expected to be answered in preparation antibacterials
With, belong to first public, and it is strong for bacteriostatic activity, possess prominent substantive distinguishing features, be simultaneously used for antibacterial sense
The preventing and treating of dye obviously has the most progressive.
Detailed description of the invention
The preparation method of compound Cyclomarinone involved in the present invention and Maristachones E sees document
(Almeida C, et al., Unprecedented polyketides from a marine sponge-associated
Stachylidium sp.J Nat Prod, 2013,76 (3): 322-326.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by specific embodiment
Any restriction, but be defined in the claims.
Embodiment 1: the preparation of compound composition tablet involved in the present invention:
Take 7 g of compound Cyclomarinone and 3 grams of Maristachones E, add 190 grams of dextrin, mixing, routine
Tabletting makes 1000.
Embodiment 2: the preparation of compound composition capsule involved in the present invention:
Take 7 g of compound Cyclomarinone and 3 grams of Maristachones E, add starch 190 grams, mixing, fill glue
Capsule makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example 1: the experimentation of antibacterial activity of the present invention
Antibacterial activity test is the method using concentration dilution, measures in triplicate every time, test pathogen have escherichia coli,
Fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus, bacterial concentration is 105Individual/mL.Of the present invention group
Compound initial concentration is 50.0 μ g/mL (5% dimethyl sulfoxide DMSO), gradient dilution to 0.098 μ g/mL, equivalent volumes
Bacterium solution and test sample are mixed in 96 orifice plates, and antibacterial culturing temperature is respectively 37 DEG C, observe after incubation time 24h,
If being sample lowest concentration of antimicrobial, i.e. MIC value when finding and do not have bacterium colony to be formed.This experiment positive control is amikacin sulfate,
The anti-bacterial result of the present invention is shown in Table 1, and medicine of the present invention uses above-described embodiment 1 method to prepare, and separately sets individually oriented compound I with independent
Compound II matched group.
The antibacterial MIC value of table 1 present invention (μ g/mL)
Conclusion: the present invention has the strongest antibacterial activity, and therefore the present invention is expected to be used for preparing novel antibacterial medicine, this
Bright also have antibacterial actions, and effect is substantially better than individually oriented compound I and individually oriented compound II matched group.
Claims (4)
1. an anti-bacterial drug compositions, it is characterised in that the active component of said composition is by compound I and chemical combination
Thing II forms, and in said composition, the mass percent of compound I and compound II is respectively 70% and 30%, described
Shown in the structure of compound I such as formula (I), shown in the structure such as formula (II) of described compound II:
2. anti-bacterial drug compositions as claimed in claim 1, it is characterised in that: preparation method is by compound I's
The powder of powder and compound II is sufficiently mixed according to mass percent respectively 70% and 30%, adds adjuvant, makes
Preparation.
3. anti-bacterial drug compositions as claimed in claim 2, it is characterised in that: adjuvant is dextrin or starch.
4. anti-bacterial drug compositions application in anti-bacterial drug as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610249267.3A CN105902532A (en) | 2016-04-19 | 2016-04-19 | Anti-bacterial medicine, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610249267.3A CN105902532A (en) | 2016-04-19 | 2016-04-19 | Anti-bacterial medicine, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105902532A true CN105902532A (en) | 2016-08-31 |
Family
ID=56746485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610249267.3A Pending CN105902532A (en) | 2016-04-19 | 2016-04-19 | Anti-bacterial medicine, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105902532A (en) |
-
2016
- 2016-04-19 CN CN201610249267.3A patent/CN105902532A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| CELSO ALMEIDA ET AL.: "Unprecedented Polyketides from a Marine Sponge-Associated Stachylidium sp.", 《 J. NAT. PROD.》 * |
| JUAN LIU ET AL.: "Antibacterial Polyketides from the Jellyfish-Derived Fungus Paecilomyces variotii", 《J. NAT. PROD.》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103251611A (en) | Application of Aspeverin in preparation of anti-bacteria medicines | |
| CN105902532A (en) | Anti-bacterial medicine, preparation method and application thereof | |
| CN102872105B (en) | Application of Houttuynoid C in antibacterial medicine | |
| CN103446125B (en) | Lycojaponicumin B is preparing the application in anti-bacterial drug | |
| CN103462968B (en) | Incarviatone A is preparing the application in anti-bacterial drug | |
| CN102861076B (en) | Application of Houttuynoid A in antibacterial medicine | |
| CN102872090B (en) | Application of Houttuynoid D in anti-bacterial agents | |
| CN102895238B (en) | Application of Gypensapogenin A in antibacterial medicament | |
| CN103638010B (en) | Application of Artoxanthochromane in antibacterial drugs | |
| CN102872030B (en) | Application of Gypensapogenin B in antibacterial drugs | |
| CN103381164B (en) | Chukrasone A is preparing the application in anti-bacterial drug | |
| CN103462982B (en) | Spirooliganones B is preparing the application in anti-bacterial drug | |
| CN103381153B (en) | Chukrasone B is preparing the application in anti-bacterial drug | |
| CN103446114A (en) | Applications of Sarcaboside A in antibacterial medicament | |
| CN103027907A (en) | Application of Aphanamixoid A in preparation of antibacterial drugs | |
| CN103463037B (en) | Lycojaponicumin A is preparing the application in anti-bacterial drug | |
| CN103463075B (en) | Lycojaponicumin C is preparing the application in anti-bacterial drug | |
| CN102872146A (en) | Application of Houttuynoid D in antibacterial drugs | |
| CN105412091A (en) | Application of Daphnilongeranine C in preparing antibacterial drugs | |
| CN102895251A (en) | Application of Houttuynoid E in antibacterial drugs | |
| CN103356517B (en) | Application of Scopariusins in preparation of antibacterial medicines | |
| CN105287536A (en) | Application of castanospermine to preparation of antibacterial drugs | |
| CN105395559A (en) | Application of Astataricusones A in preparation of antibacterial drugs | |
| CN105078961A (en) | Antibacterial medicine and application thereof | |
| CN103446106A (en) | Applications of Sarcaboside B in antibacterial medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |
|
| WD01 | Invention patent application deemed withdrawn after publication |